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Traumatic brain injury (TBI) is an important cause of morbidity and mortality in the developing 
world, and remains the leading cause of death and long-term disability in young adults. 
Hypocoagulopathy is a well described sequela of severe TBI and is associated with prolonged 
intensive care unit stays and poor outcomes. This study was conducted to determine the 
prevalence of coagulopathies in patients with severe, isolated TBI. The secondary outcome 
was to note any difference in the prevalence of detected coagulopathy between blunt and 
penetrating TBI.  
Methods 
This is a prospective observational study of fifty patients with severe, isolated TBI (AIS head 
>3, AIS body <3), presenting to, or were referred to Groote Schuur Hospital. We drew blood 
for International Normalised Ratio (INR), activated partial thromboplastin time (aPTT), 
platelets count, sodium, potassium, urea and thromboelastography (TEG) on all patients at 
12 hours (±3 hours), 36 hours (±3 hours) and eligible patients at 60 hours (±3 hours) post 
injury. Coagulopathy was defined as any one of the following: platelet count<120 x 109/L, 
INR>1.2, PTT>37 seconds, R time<4 minutes or >8 minutes, K time>4 minutes, α angle<47˚ or 
>74˚, maximum amplitude<54 mm or >72mm, EPL>15%, LY30>8 %, coagulation index<-3 or 
>3.  
Results 
The patients were mostly male (n=47), with a mean age of 31 years. Median AIS head and 
body were 5 and 1, respectively. Thirty-six patients sustained blunt, and the remaining 14 
penetrating trauma. Sixteen of the fifty patients demised during the course of the study. The 
cumulative prevalence of coagulopathy, as diagnosed by TEG, was 84% as diagnosed by TEG. 
Of the total 109 TEGs, 59 samples were hypercoagulable, 10 were hypocoagulable and the 
remaining 40 normal. There was poor correlation between laboratory-based coagulation 




Contrary to what is reported in the literature, we found little evidence of a hypocoagulable 
state as defined by TEG (10 of the 109 samples). Many patients were significantly 
hypercoagulable (59 of the 109 samples) according to criteria specified by the TEG 
manufacturer. When considering the CBT results, we had a much higher number of 
hypocoagulable samples (72 of the 109 samples), with none showing a hypercoagulable state. 
Moreover, there was poor correlation between coagulation status as measured by TEG 
described and that found on conventional blood testing. No significant differences in the 
prevalences of coagulopathy amongst blunt and penetrating mechanisms of injury were 
noted. Some differences in fluid balance and presenting vitals in the hypocoagulable group 
when compared to the normal and hypercoagulable groups were noticed, but this does not 
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Traumatic brain injury (TBI) is defined as a non-degenerative, non-congenital insult to the 
brain from an external mechanical force causing temporary or permanent neurological 
dysfunction, which may result in impairment of cognitive, physical or psychosocial functions, 
with an associated diminished or altered state of consciousness (Dawodu, 2015). Changes 
initiated by TBI can persist for months or years after injury and significantly affect the quality 
of life of not only the head-injured patients, but also their immediate families (Bramlett and 
Dietrich, 2015). Much of the economic burden of TBI is related to the resultant long term loss 
of productivity (Humphreys et al., 2013). Furthermore, TBI can lead to progressive brain 
atrophy and an increased vulnerability to neurodegenerative disorders (Bramlett and 
Dietrich, 2015).  
TBI is an important cause of morbidity and mortality in the developing world (Hyder, 2007), 
and remains the leading cause of death and long-term disability in young adults. The overall 
prevalence of TBI in developed countries is 200 per 100 000 population per year. The South 
African prevalence was reported as 316 per 100 000 population per year (Nell, 1991). These 
numbers are likely to be a gross underestimate as very mild TBI (not requiring hospitalisation) 
and severe TBI (death on scene or before hospital admission) may not be accounted for in 
epidemiological reports (Corrigan et al., 2010). Despite a comprehensive attempt to count all 
contacts with the medical system, many injuries receive no treatment or treatment may not 
be recorded in medical record documentation. One study found that 42% of a convenience 
sample of persons reporting TBI had not received any treatment for it (Setnik and Bazarian, 
2007). Furthermore, untreated TBI is common in military personnel engaged in combat and 
those unlikely to seek medical care; such as persons involved in sports, those who experience 
domestic violence and substance abusers. Most studies of incidence and prevalence are 
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based on civilian healthcare statistics. Therefore, all methods of estimating the incidence and 
prevalence underestimate the number of affected individuals due to uncounted cases 
(Corrigan et al., 2010).  
A 2007 study found injury-related mortality rates in South Africa to be six times higher, and 
the incidence of road traffic injuries to be double that of the global rate (Norman, 2007). 
Homicide and interpersonal violence was the leading cause of injury death in this study, 
followed by road traffic injuries and suicide or self-inflicted violence. Income inequality and 
poverty, high unemployment, rapid social change, corruption and poor rule of law, gender 
inequalities and family breakdown as well as drugs and alcohol were cited as major 
contributors. 
A 2015 study conducted in KwaZulu Natal, South Africa (Lewis and Wood, 2015) found that 
of the 10390 patients included in their study, interpersonal violence (IPV) was responsible for 
25% of injuries and 54.7 % of deaths. Most isolated head injuries were caused by IPV in this 
study. Furthermore, of those who died, 21.4% suffered an isolated head injury. This 
demonstrates the high rate and burden of head injuries in South Africa.  
COAGULOPATHY AND PREVALENCE 
Hypocoagulopathy is a well-recognised sequela of severe traumatic brain injury (Zehtabchi et 
al., 2008) and is frequently associated with prolonged intensive care unit (ICU) stays and 
unfavourable outcomes (OR 3.75 [CI 95% 1.07-12.51; p=0.04]) (Greuters et al., 2011). The 
mere presence of a hypocoagulable state was found to increase the likelihood of a poor 
outcome by a factor of 36 and the odds of mortality by five- (de Oliveira Manoel et al., 2015) 
to ninefold (Kumar, 2013). The presence of a hypocoagulable state can predispose patients 
to progressive haemorrhagic injury (PHI), which in turn leads to a fivefold higher mortality 
(Maegele, 2013) and fewer hospital free days (Folkerson et al., 2015).  
Two separate meta-analyses (Epstein et al., 2014, Harhangi et al., 2008) quote the incidence 
of hypocoagulopathy (as defined by investigators in each individual study; generally 
international normalised ratio [INR]>1.2, platelet count [PLT]<100 x 109/L, or disseminated 
intravascular coagulation [DIC] score>2) in TBI to be one in three patients and 35% of patients 
on presentation to hospital. However, varying reports document an incidence between 10%; 
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as diagnosed by prolonged activated partial thromboplastin time (aPTT), elevated fibrin 
degradation product (FDP) concentration, or PLT<100 x 109/L (Chiaretti et al., 2002) and 72%; 
as diagnosed by a modified coagulopathy score (Kuo et al., 2004). Some of this variation is 
partly due to the differing criteria used for the diagnosis of coagulopathy, and some due to 
the improvement in sensitivity of laboratory testing (Harhangi et al., 2008).  
As our understanding of the complex process of coagulation has evolved and improved, 
different criteria have been implemented to make the diagnosis of a hypocoagulable state. 
Chiaretti et al. diagnosed the presence of DIC both by the clinical presence of organ 
dysfunction and abnormal laboratory criteria (prolonged prothrombin time [PT] and aPTT, 
elevated FDP concentration and PLT<100000 mm3 or a rapid decline in PLT) (Chiaretti et al., 
2002). While this is a practical approach to patient management and mirrors the common 
practice of treating the patient and not the number, the 100% mortality of the patients that 
were diagnosed with DIC displays the high specificity but exposes the lack of sensitivity. Kuo 
et al used a modified DIC score (Kearney et al., 1992), which relies on a combination of 
laboratory variables (PT, PTT, PLT, fibrinogen and D-dimer) to make the diagnosis. While 
mortality amongst those who had a modified DIC score of  4 was 90%, 8 of the 10 patients 
that met the criteria for this group had fixed and dilated pupils, and 7 had more than 15 mm 
midline shift on the CT scan (Kuo et al., 2004). While not totally devoid of benefit, it is difficult 
to motivate for the need for conventional laboratory tests, many of which were designed with 
a different purpose in mind, in the era of viscoelastic testing (VET).  
Hypercoagulopathy is not well studied in TBI patients, partly due to the fact that conventional 
blood testing is unable to detect this clinical state. While trauma patients have been noted to 
be hypercoagulable for the first 24 hours post injury (Schreiber et al., 2005), as diagnosed by 
measuring thrombin activation (decrease in thrombin-antithrombin complex levels from 
3415 L on day 1 to 188L on day 4 [p<0.01]) that correlated with thromboelastography 
(TEG) diagnosed hypercoagulable state, there are no studies using conventional blood tests 
to investigate this in TBI patients. Hypercoagulability as defined by TEG has been described 
up to 7 days following moderate to severe TBI (Glasgow Coma Scale [GCS]<12), however no 
conventional blood tests were done in this study, so the relationship between the two 




Current evidence (Kumar, 2013, Maegele, 2013, Wijayatilake et al., 2015), based on both 
human and animal work, suggests that activation of the coagulation cascade due to massive 
tissue factor release from the injured brain initially creates a hypercoagulable state. This is 
followed by a microvascular thrombosis-related consumptive coagulopathy similar to that 
seen in DIC. The result is a hypocoagulable state, which is further compounded by 
hyperfibrinolysis. Comprehensive analysis of various biomarkers in both head injured and 
non-head injured patients did not show any significant differences in plasma levels of the 
biomarkers, although patients with isolated TBI had significantly higher 30-day mortality (22 
% vs. 5%) (Genet et al., 2013). 
Various alternate and conflicting theories have been proposed, including a hypo perfusion 
mediated protein C dysregulation theory (Sillesen et al., 2014), a platelet dysfunction theory 
(Nekludov et al., 2007), a platelet hyperactivity theory (Kumar, 2013) and a micro particle 
upregulation theory (Morel et al., 2008).  
Protein C theory 
The protein C theory postulates that in the presence of tissue hypoperfusion in the acute 
phase of TBI, the vascular endothelium expresses thrombomodulin, resulting in activation of 
the protein C pathway. The activated protein C decreases plasminogen activator inhibitor 
(PAI)-1 levels and increases tissue plasminogen activator (tPA), resulting in hyperfibrinolysis 
(Cohen et al., 2007, Sillesen, 2014). The posttraumatic inflammatory response could result in 
chronic depletion of protein C, leading to a reduction in the inhibition of coagulation and lysis 
and therefore promoting a hypercoagulable phase (Maegele, 2013). Thus, a combined hypo- 
and hypercoagulable state exists. 
Platelet dysfunction theory 
The platelet dysfunction theory originates from a clinical study investigating TEG platelet 
mapping, that revealed that platelet function in TBI differs from that in trauma cases without 
TBI or even chronic alcoholic patients (Nekludov et al., 2007). The main difference found in 
this study was clearly reduced arachidonic acid (AA) activity in TBI cases, indicating impaired 
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function of the platelet cyclooxygenase and/or thromboxane receptors. This may partly 
explain the altered bleeding time in these patients. In a rat model, a relationship between the 
severity of injury and the degree of adenosine diphosphate (ADP) receptor inhibition was 
shown, with significant ADP receptor inhibition as early as 15 minutes post injury (Castellino 
et al., 2014). In a separate rat model study (Donahue et al., 2014), marked ADP receptor 
inhibition (24.8% 6.2 vs. control 65.1% 3.4) was depicted from 15 minutes post injury and 
throughout the hour that coagulation was monitored. In contrast, AA receptor inhibition was 
worst at 30 minutes post injury. In a swine model, platelets activated with ADP showed a 
lower aggregation at 15 minutes post injury (65.1 U vs. 80.4 U, p=0.02) and maintained this 
difference at the follow-up 2-hour observational time-point (62.7 U vs. 73.5 U, p<0.01). This 
ADP receptor dysfunction was noted to be associated with increased levels of platelet 
activation marker transforming growth factor (TGF)- (Sillesen, 2014). A prospective 
observational human study confirmed ADP receptor dysfunction (61.2% [IQR 43.1-95.4%)] vs. 
15.5% [IQR 12.2-31.6%]) which was found to correlate with the severity of TBI (Davis et al., 
2013). The same study also reported poor correlation between platelet numbers and 
function, implying that platelet count is a poor marker for the presence of coagulopathy. 
Interestingly, this platelet dysfunction does not improve with transfusion of platelets (Briggs 
et al., 2015). Importantly, patients found to have ADP receptor dysfunction had a higher in-
hospital mortality (32% vs. 8%; p<0.01) (Daley et al., 2016). 
Platelet hyperactivity theory 
Platelet hyperactivity in TBI is believed to be multifactorial in origin (Kumar, 2013). There may 
be upregulation of a disintegrin and metalloprotease with a thrombospondin type 1 motif, 
member 13 (ADAMTS-13), which is essentially responsible for cleaving the prothrombotic 
ultralarge von Willebrand factor forms into smaller haemostatically active but no longer 
prothrombotic multimers. Von Willebrand factor is a strong stimulus for platelet activation 
and adhesion. Together with excessive platelet receptor activation and release of platelet-
activating factor (PAF) microthrombus formation occurs. Furthermore, PAF enhances blood-
brain barrier (BBB) permeability, promotes oedema formation and release of prothrombotic 
mediators in the systemic circulation. 
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Microparticle upregulation theory 
The microparticle upregulation theory suggests that cells may release microparticles (MPs) 
upon activation and cell death. It is thought that these MPs can then play a role in triggering 
coagulation and inflammation. A small (n=16) observational study in human TBI (Morel et al., 
2008) showed a significant increase in mean procoagulant MPs of platelet and endothelial 
origin in the cerebrospinal fluid when compared to controls (4.51.8 vs. 0.830.28 nM Phtd-
Ser Eq; p=0.0014). The levels decreased progressively over the first ten days following injury. 
The authors suggest two possible theories for the appearance of MPs in the cerebrospinal 
fluid: increased permeability of the BBB in response to proinflammatory mediators such as 
histamine, bradykinin, AA, and nitric oxide, and direct migration via injured vessels or from 
blood in the spinal fluid. A small but fascinating human study (Nekludov et al., 2014) shows 
not only that severe TBI results in increased levels of circulating MPs, but also confirms a 
transcranial gradient. These results suggest that MPs released from endothelial cells may 
carry tissue factor out into the circulation, which may have procoagulant and 
proinflammatory effects. A murine model of moderate head injury showed that platelet 
contribution to clot formation is decreased around 1 day after TBI, and is likely associated 
with altered MP populations, with a significant increase in procoagulant MP activity (Midura 
et al., 2015).  
A murine model of TBI designed to investigate the aetiology of microthrombus formation 
found that 60% of all cerebral vessels (ipsilaterally, but outside the contusion area) were 
occluded by microthrombi as detected 24 hours after injury by two-photon microscopy 
(Schwarzmaier et al., 2016). Importantly, the investigators did not detect any improvement 
following factor XI (FXI) inhibition, implying that microthrombus formation is driven by the 
extrinsic coagulation pathway. They postulate that prophylactic anticoagulation via inhibition 
of FXI activation by FXIIa (activated factor XII) may be of therapeutic value pending further 
studies.  
Role of neuroinflammation 
Neuroinflammation is a secondary wave of biochemical cascades, resulting in metabolic and 
cellular changes that occur within seconds to minutes after the primary injury, and can persist 
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for months or years. While excitotoxicity, oxidative stress, mitochondrial dysfunction and 
inflammation can individually result in cell death, interaction amongst the processes worsen 
the outcome following TBI. Of note, excessive microglial activation results in excessive release 
and upregulation of proinflammatory cytokines such as tumour necrosis factor (TNF) , 
interleukin (IL)-1, IL-6, IL-12 and interferon (IF) . Higher expression of cell adhesion 
molecules in the endothelial cells and increased production of chemokines increases the 
permeability of the BBB and results in an increased inflammatory response. Interestingly, 
activated microglia can polarise into distinct phenotypes depending on the microenvironment 
in which they are activated (Lozano et al., 2015). When exposed to cytokines IL-4 and IL-13, 
microglia reduce proinflammatory cytokines and increase the production of antiinflammatory 
cytokines such as IL-10 and TGF-1. Modulating inflammatory cells and promoting an anti-
inflammatory phenotype may prove to be future drug targets in TBI.  
Role of alcohol and the adrenergic response 
Acute alcohol related blunting of the adrenergic response may play a role in mitigating the 
early coagulopathy seen in TBI. A recent study (Lustenberger et al., 2011) found that patients 
who were intoxicated on presentation to hospital had a significantly lower incidence of early 
coagulopathy (5.4% vs. 15.3%; adjusted p<0.001) and in-hospital mortality (9.8% vs. 16.6%, 
adjusted p=0.011; adjusted OR 0.39 [CI 95% 0.19-0.81]). A major limitation in this study was 
the administration of pharmacological withdrawal prophylaxis by means of barbiturate, 
benzodiazepine, dexmedetomidine or propofol administration, all of which are known to 
decrease adrenergic activity and cerebral metabolism following TBI, and may have affected 
survival amongst these patients. A recent study (Cook et al., 2015) in acutely intoxicated 
trauma patients showed a relatively hypocoagulable state on TEG (longer R time, smaller  
angle, lower maximum amplitude [MA]; but not necessarily abnormal values as defined by 
the manufacturer) that was associated with reduced incidence of DVT (1.4% vs. 16.2%, 
p<0.01; OR 0.2 [CI 95% 0.05-0.79]). There was no associated change in conventional blood 
test (CBT) results (aPTT, fibrinogen, INR, platelet count or hemoglobin) amongst the two 
groups. 
Thus, the aetiology of coagulopathy in TBI is most likely multifactorial. 
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SEVERITY OF INJURY AND PREVALENCE OF 
COAGULOPATHY 
Most of the studies that investigated the relationship between severity of head injury and risk 
of coagulopathy use CBTs. In a study looking at immunofluorescent staining in brain injured 
rats and pigs (n=18), as well as specimens of contused human brain (n=11) removed during 
surgical decompression, a strong and direct relationship was seen between the severity of 
coagulopathy and the density of intravascular coagulation (Stein et al., 2002). Severe, isolated 
TBI has been shown to be independently associated with increased coagulopathy 
(Lustenberger et al., 2010, Cap and Spinella, 2011) as measured by INR (coagulopathy was 
defined as INR >1.4 and 1.5, respectively). In contrast, a recent prospective study (Juratli et 
al., 2014) found that unfavourable short and long term neurological outcome after isolated 
TBI was determined by early haemorrhagic progression of injury and coagulopathy (as 
documented on CBT) and was irrespective of the severity of the trauma. It is important to 
note that in this study, 31% of patients underwent early neurosurgery, with an unknown 
number receiving blood products to correct the coagulation abnormalities, which could have 
impacted the reported results.  
TIME COURSE OF COAGULOPATHY 
Description of the time course of coagulopathy in TBI literature is inconsistent and somewhat 
limited. Most studies report abnormal coagulation within minutes and lasting for 24 hours 
post injury (Stein and Smith, 2004), whereas others report abnormal results up to 7 days post 
injury (Massaro et al., 2014). A study (Lustenberger et al., 2010) that aimed to investigate the 
time course of coagulopathy found that the onset was within 12 hours in 45% of patients and 
within 24 hours in 65% of patients, with the duration of coagulopathy varying from 24 to 72 
hours. These investigators suggest monitoring patients for up to 5 days post injury. Of course, 
the sensitivity of the tests used to detect coagulopathy will influence the reported duration.  
It has been suggested that the time of onset of coagulopathy may have predictive value for 
patient outcomes. In one study (Franschman et al., 2012), investigators found that 
delayed/sustained coagulopathy was more frequently associated with computed tomography 
(CT) abnormalities (intracranial haemorrhage and signs of raised intracranial pressure), higher 
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in-hospital mortality (51% vs. 33%; p<0.05) and unfavourable outcomes at 6 months post TBI 
when compared to early, short-lasting coagulopathy. In contrast, another study reported that 
early coagulation abnormalities were associated with a higher incidence of overall 
complications (Lustenberger et al., 2010). 
CONVENTIONAL BLOOD TESTING 
CBT for prolongation of the PT, INR, aPTT, and PLT may elucidate an underlying 
hypocoagulopathy. Currently, there are few conventional laboratory tests that aid in the 
detection of hypercoagulable states.  
INR and aPTT 
INR was originally developed to assess the adequacy of dosing of vitamin K antagonists. Only 
a small fraction of the coagulation pathway is examined by this plasma based test that was 
designed neither to evaluate coagulopathy in acutely bleeding patients (McCully et al., 2013) 
nor to predict whether patients are at an increased risk for bleeding after procedures (Segal 
et al., 2005). Raised INR may point towards a hypocoagulable state, but the absence of a 
raised INR does not necessarily exclude this. In TBI patients, the most significant peak in INR 
was at 6 hours with another smaller peak at 36 hours (Lustenberger et al., 2010). However, 
at the time of the first peak in this study, the subjects were likely to have normal platelet 
counts. This somewhat decreases the practical and clinical importance of this finding, and 
shows how the presence of a raised INR can confuse the decision making that influences 
patient care. Furthermore, in a recent retrospective observational study (Rowell et al., 2014), 
patients who had a raised INR (>1.4) took longer to receive their neurosurgical intervention 
(median time 358 minutes [285-478 minutes] vs. 184 minutes [87-343 minutes]), were more 
likely to receive plasma transfusion (70% vs. 24%, p=0.004), and received more units of 
plasma (2 U [0-6U] vs. 0 U [0-1U], p=0.006). 
The potential relationship between aPTT and progressive head injury was examined in a 
systematic review (Zhang et al., 2015). No significant association was shown due to the 





Thrombocytopenia complicates TBI in 10% of cases, resulting in a 35% increased risk of 
mortality at 6 months (Kumar, 2013, Van Beek et al., 2007). A platelet count of less than 100 
x 109/L was an independent predictor of progression as diagnosed on repeat head CT scan 
(OR=4 [CI 95%=1.7-10]), need for neurosurgical intervention (OR 3.6 [CI 95%=1.2-6.1]) and 
mortality (OR 2.6 [CI 95%=1.1-4.8]) (Joseph et al., 2014). 
D-dimer 
D-dimer, an end-product of both coagulation and fibrinolysis may be one marker of a 
hyperfibrinolytic state, and may suggest the presence of a hypercoagulable state. In humans, 
D-dimers have been found to correlate with the severity of brain injury as well as with the 
chances of progressive haemorrhagic injury (PHI) (Tian et al., 2010). In this study, a d-dimer 
above 5 mg/L was found to have a strong link with progression of haemorrhagic injury (OR 
11.85 [CI 95% 5.67 – 24.75, p=0.000]). A systematic review (Zhang et al., 2015) of the literature 
determined that raised d-dimer was associated with PHI with a pooled OR of 16.5 (CI 95% 
4.94-55.04; p<0.001). D-dimer seems to be an acute phase reactant for haemostatic function, 
with the value increasing within an hour from the injury (Nakae et al., 2016). Further increases 
were noted up to 3 hours post injury, followed by a significant decrease. Unfortunately, d-
dimer is not a very specific marker for coagulopathy and may be elevated in other 
inflammatory states such as infection, malignancy and pregnancy, to name a few. 
ABNORMAL CONVENTIONAL BLOOD RESULTS AND 
OUTCOME 
A post hoc analysis on data from IMPACT (International Mission on Prognosis and Analysis of 
Clinical Trials in TBI) (Van Beek et al., 2007), which evaluated the prognostic value of 
admission laboratory tests, found a clear and individual relationship between PT, INR, aPTT 
and PLT and poor outcome. PT prolongation (>20 seconds) was associated with a 64% 
increase in risk of mortality and 42% increased risk of unfavourable outcome (Kumar, 2013, 
Van Beek et al., 2007). Elevated INR was shown to be independent of age in a logistic 
regression analysis for both radiologic (OR 2.4 [CI 95% 1.1-11.1, p=0.04]) and clinical 
17 
 
deterioration (OR 9.0 [CI 95% 1.4-58; p=0.02]) in a small subset of patients with traumatic 
subarachnoid hemorrhage (von der Brelie et al., 2015). It is noteworthy that of the 34 patients 
that showed features of hypocoagulopathy on CBT, 16 were known to be on aspirin, and 2 
were on simultaneous aspirin and warfarin treatment. Similarly, patients with traumatic 
subdural hematoma and coagulopathy had a significantly worse outcome, with twice the in-
hospital mortality (55% vs. 23%, p<0.001) of noncoagulopathic patients with similar severity 
of injury (Lemcke et al., 2014). 
Apart from having an increased length of ICU stay, fewer ventilator-free days, and increased 
mortality, coagulopathic patients are more susceptible to other complications such as sepsis 
(29.9% vs. 1.3%, adjusted p=0.003) and diabetes insipidus (28.3% vs. 2.6%, adjusted p=0.003) 
(Lustenberger et al., 2010).  
A recent meta-analysis (Yuan et al., 2016) sought to evaluate whether isolated TBI induces 
pronounced coagulopathy and to examine any relationship with PHI. After evaluating a total 
of 19 studies, the investigators found that the PHI group had a lower platelet count (pooled 
mean of sample of difference scores [MD] -19.21 [CI 95% -26.99 to -11.44, p<0.001]) and a 
slightly higher INR value (pooled MD 0.07 [CI 95% 0.02-0.13, p=0.006]) when compared to the 
non-PHI group. There was no difference in mean aPTT and PT amongst the groups. PHI was 
found to be associated with a higher percentage of INR>1.2 (pooled OR 3.49 [CI 95% 1.97-
6.20, p<0.001]), PLT<100x109/L (pooled OR 4.74 [95% CI 2.44-9.20, p<0.001]) and 
coagulopathy (pooled OR 2.52 [CI 95% 1.88-3.38; p<0.001]). This is in keeping with the 
findings that PT, D-dimer level and INR value are positively associated with a risk of PHI, 
whereas higher platelet count and fibrinogen suggest a lower risk of PHI (Zhang et al., 2015). 
Interestingly, no difference in coagulation status between the isolated TBI group and those 
injured elsewhere on the body was noted. This challenges the theory that severe TBI may 
result in exaggerated coagulation changes when compared to other areas of the body (Yuan 
et al., 2016).  
From the foregoing literature review, it is clear that the most dreaded and devastating 
consequence of the hypocoagulable state that has been linked to severe TBI is PHI. 
Transfusion of platelets or fresh frozen plasma (FFP) to correct thrombocytopaenia and 
coagulopathy respectively, has naturally been explored as a means to minimise the risk of 
secondary complications. However, blood and blood product transfusion present their own 
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subset of risks to the patient such as transfusion related acute lung injury (TRALI), transfusion 
associated circulatory overload (TACO), various immune reactions and infection. A recent 
retrospective review (Anglin et al., 2013) shows that overall, in TBI patients with moderate 
coagulopathy (INR 1.4-2.0), FFP transfusion alone or in combination with packed red blood 
cells (PRBCs) were associated with poorer long-term functional outcomes as measured by the 
Glasgow Outcome Scale – Extended (GOSE). In the moderate coagulopathy group, patients 
who received FFPs were more likely to have a lower GOSE score (OR 5.2 [CI 95% 1.72-15.73]), 
and patients who received both FFPs and PRBCs were even more likely to have a lower GOSE 
score (OR 7.17 [CI 95% 2.12-24.12]). Platelet transfusion was not significantly associated with 
outcome in this study. This highlights the need for better transfusion triggers in severe TBI. 
THROMBOELASTOGRAPHY 
TEG may be used as a tool for the global assessment of coagulation due to its unique ability 
to identify and assess all phases of haemostasis, and thus allow for the diagnosis of both hypo- 
and hypercoagulable states. TEG has been extensively validated in trauma-induced 
coagulopathy as a point-of-care test, and has been used effectively to identify transfusion 
triggers in such patients (Johansson et al., 2009, Johansson, 2010, Schochl et al., 2012, Da Luz, 
2014).  
Determining the prevalence of hypercoagulability as detected by TEG and comparing it with 
that detected with conventional laboratory values, may be beneficial in determining the need 
for anticoagulation in patients with TBI, as the risk for venous thromboembolism in these 
patients has been found to be three- to fourfold higher than trauma patients without TBI 
(Reiff et al., 2009). An older but interesting study (Schreiber et al., 2005) noted that 
hypercoagulability as diagnosed by a shortened R-time on TEG was the main coagulation 
abnormality in trauma patients (Injury Severity Score ranging from 11 to 35) during the first 
four days after injury. They found that 62% of patients were hypercoagulable by TEG on day 
1, and 26% up to day 4 post injury. Women were found to be more hypercoagulable when 
compared to men (R time 2.90.7 mm vs. 3.91.5 mm). Importantly, this hypercoagulable 
state was not detected by means of any of the CBTs, which were all normal throughout the 
duration of the study. There are some limitations to this study: it is unclear whether some, if 
any, of their study cohort had significant TBI or not, and the use of pharmaceutical deep 
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venous thrombosis (DVT) prophylaxis in 19 patients. Lastly, a small study has noted the 
presence of late hypercoagulability as diagnosed on TEG up to 120 hours following TBI 
(Massaro et al., 2014). 
TEG associated hypocoagulopathy as detected in less than 10 percent of patients, has been 
shown to be a predictor of poor outcome (increased mortality, fewer ICU-free and hospital-
free days) in patients with TBI (Windelov et al., 2011). In this retrospective observational 
study, hypocoagulopathy as diagnosed by TEG at neurosurgical ICU admission was associated 
with clinical deterioration (57% vs. 16%, p=0.02) and worse outcome (30-day mortality 63% 
vs. 16%, p=0.008). In the same study, they found no such association with hypocoagulopathy 
detected by CBT, implying that TEG may be better at detecting a clinically relevant 
hypocoagulopathy. Moreover, such hypocoagulopathy has been linked with an increased 
need for neurosurgical intervention. The presence of coagulation abnormalities in patients 
undergoing emergent neurosurgery may critically affect the patients’ course, both in theatre 
and perioperatively. 
COAGULOPATHY AND MECHANISM OF INJURY 
Very few studies have been pursued to detect differences in coagulation between blunt and 
penetrating mechanisms of injury, perhaps because of difficulty in recruiting an adequate 
number of patients with penetrating head injuries. One study from 1986 found that hypoxia, 
anaemia, hypotension and DIC were associated with worse outcome on the Glasgow 
Outcome Scale (GOS)(Kaufman et al., 1986). A large observational study (Black et al., 2002) 
with the aim of determining a difference in the incidence and type of medical complications 
and comorbidities between blunt and penetrating head injuries was conducted. More than 
50% of patients in this study suffered one or more associated injuries or developed at least 
one medical complication. Penetrating injuries were associated with higher rates of medical 
complications, especially those involving the pulmonary and central nervous systems. They 
found no statistically significant difference in the incidence of coagulopathy between the two 
groups (7% in the penetrating group vs. 3% in the blunt group), but had a low number (n=12, 
sample size 317) of patients in whom coagulopathy was detected. Furthermore, they fail to 
outline the criteria for diagnosing coagulopathy.  
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In TBI, the time course and required neurosurgical interventions vary by mechanism of injury. 
Not only were patients with penetrating brain injury more likely to require a neurosurgical 
intervention (penetrating 51.8% vs. blunt 21.2%), but they were also more likely to have any 
of the specific interventions, e.g. intracranial pressure (ICP) monitoring (32.2% vs. 16%) and 
craniectomy (24% vs. 5.2%)(Orman et al., 2012). 
SUMMARY 
In summary, the literature reports wide variations in the prevalence of coagulopathy, with 
hypocoagulopathy being the predominant pathology. In our experience, the prevalence of 
hypocoagulopathy seems to be much lower than the reported value of 35 percent. 
Furthermore, the time course of onset and duration of coagulopathy has been inadequately 
defined in the literature. To provide a good standard of care for our patients by preventing 
secondary insults and minimizing unnecessary transfusion of blood and blood products, it is 
vital to know and understand the underlying characteristics of coagulopathies. To the best of 
our knowledge, no study has assessed the prevalence of coagulation abnormalities in isolated 
and severely head-injured patients by means of both conventional blood testing and TEG over 
multiple time points. Furthermore, we suspected that conventional blood tests may 
overestimate the presence of coagulopathy which may not bear clinical significance.  
The purpose of this study was to determine the prevalence of coagulation abnormalities in 
the severely head-injured South African population presenting to Groote Schuur Hospital, 
both by means of conventional blood testing and viscoelastic testing (TEG). The secondary 
outcomes were to note any differences in prevalence detected by the two methods of testing 
or by mechanism of injury (blunt vs. penetrating) as well as to detect any relationships with 
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METHODS 
Study design 
We conducted a prospective pilot observational study at Groote Schuur Hospital (GSH) in 
Cape Town, South Africa. Both the Human Research Ethics Committee (HREC) of the 
University of Cape Town and the Chief Operations Officer of Groote Schuur Hospital approved 
the study. Due to the nature of their injuries, patients were unable to give consent. The need 
for delayed consent or proxy consent was waived by the HREC in view of the minimal risk 
posed to the patients. Fifty patients admitted to GSH between October 2015 and June 2016 
who fulfilled the inclusion criteria were recruited to the study. The laboratory and TEG testing 
conducted as a part of the study were not available to the clinical team and in no way affected 
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patient management. All clinical decisions that affected the patients’ management were 
made by the neurosurgical team based on the clinical condition and were independent of 
patients’ inclusion in the study.  
Sample size calculation 
Based on the meta-analysis by Harangi et al., we expected the prevalence of coagulopathy as 
defined by conventional blood testing to be around 33 percent.1 However, informal expert 
observation noted a somewhat lower number in our population. Therefore, working on an 
estimate of 15% prevalence of coagulopathy, we determined that a sample size of 39 patients 
would be required to achieve a 95% confidence interval of detecting an existing coagulopathy. 
With a sample size of 50 patients, we would achieve a 98% chance of detecting a 
coagulopathy if it were present with a prevalence between 15 and 33 percent. We therefore 
decided upon a sample size of 50 patients. 
Selection of patients 
The inclusion criteria were as follows: 
1. Adult patients (aged 18 years and over) 
2. Isolated traumatic brain injury (TBI) with  
a. Head Abbreviated Injury Score (AIS) of 3 or more (Appendix A) 
b. Chest, abdomen and extremity AIS of less than three (Appendix A) 
3. Glasgow Coma Scale (GCS) of 8 or less (Appendix B) 
Exclusion criteria were as follows: 
1. Pediatric patients (less than 18 years in age) 
2. GCS of more than 8 
3. Significant other injuries, resulting in a body AIS score of 3 or more 
4. Head AIS of less than 3 
5. Patients who received blood products prior to admission to the study 
6. Patients who have received tranexamic acid prior to admission to the study 
7. Known coagulation abnormalities 




Time zero (T0) was documented as the time of first medical contact (time of ambulance pick 
up or presentation to the emergency department). In the case of referral from another 
hospital, time of initial presentation was used when it was documented in the referral letter. 
If it was unavailable, the time of ambulance pick up for transfer was used. 
After patient selection, the following parameters were documented 
1. Age 
2. Gender 
3. GCS on presentation 
4. Mechanism of injury (blunt vs. penetrating) 
5. Time since injury/first medical contact 
6. Head AIS 
7. Body AIS 
8. Vital signs on presentation 
9. Computed tomography (CT) evaluation of intracranial injuries 
10. Neurosurgical procedures 
11. Type and volume of resuscitation fluid prior to the first sample time 
12. Administration of supplemental oxygen or fraction of inspired oxygen 
13. Blood testing included the following: 
a. Laboratory testing (Normal values can be found in Appendix C) 
i. Platelet count 
ii. International Normalized Ratio (INR) 
iii. Activated Partial Thromboplastin Time (aPTT) 
iv. Serum sodium 
v. Serum potassium 
vi. Urea 
b. Thromboelastography (TEG) (Appendix D) 
i. R time 
ii. K time 
iii.  angle 
iv. Maximum amplitude (MA) 
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v. LY30 (Clot lysis at 30 minutes after MA) 
vi. Coagulation index (CI) 
vii. G value  
For the purpose of this study, penetrating head injury was defined as that in which the dura 
mater had been breached by either a sharp object such as a knife, or high velocity projectiles 
such as in a gunshot wound, with evidence of cerebral tissue damage on CT scan. 
Blood sampling and testing 
The first blood sampling (time 1 or T1) for INR, aPTT, platelet count, sodium, potassium, urea 
and TEG was done at 12 hours (3 hours) post injury (T0+12 hours), the second (time 2 or T2) 
at 36 hours (3 hours), and if eligible, the third (time 3 or T3) at 60 hours (3 hours). The 
criteria for repeat blood sampling at 60 hours are listed in Appendix E. While there was a time 
margin of 3 hours on either side of each sampling time, most samples were taken close to the 
12 hour, 36 hour and 60 hour goals. Some patients were admitted to the neurosurgical 
intensive care unit, and already had an arterial line in situ. Strict aseptic technique was 
followed to draw blood from the existing arterial line. The dead space in our arterial line sets 
(Arrow® arterial catheterization set, TruWave™ pressure monitoring set from Edwards 
Lifesciences™) is 3 ml. As arterial lines are not heparinized at the study hospital, the first 7 ml 
of blood was aspirated and discarded prior to drawing the specimens. Most of the patients 
were still in the trauma unit at the time of collecting the first sample, therefore did not have 
an arterial line in situ, requiring a venous sample to be drawn. During phlebotomy, a venous 
tourniquet was used and strict aseptic technique was followed. All samples were drawn by a 
single investigator in the same order (clotted blood, ethylenediaminetetraacetic acid [EDTA], 
followed by citrated tubes) with a view to eliminate the possibility of tissue factor 
contamination in the citrated tubes. Patients were assigned a study number to preserve 
confidentiality.  
TEG SAMPLES 
All TEG samples were run by a single investigator on a Thromboelastograph® Hemostasis 
Analyzer 5000 (Haemoscope Corp, IL). Blood was collected in a citrated tube (BD Vacutainer®; 
0.109 M buffered Na3 citrate). All samples were run per the manufacturer’s specifications 
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(time from blood sampling to testing was between 15-30 minutes). One milliliter of the 
citrated blood was pipetted into a kaolin tube and inverted 10 times. TEG® 5000 plain cups 
were used, into which 20 L of 0.2 M CaCl2 was pipetted. Thereafter, 340 l of kaolin activated 
blood was pipetted into the plain cup. Each sample was allowed to run until LY30 was reached. 
The manufacturer’s quality control guidelines were adhered to. All contaminated specimens 
and consumables were discarded according to hospital protocols.  
LABORATORY SAMPLES 
All laboratory samples were drawn by a single investigator, labelled and taken to the on-site 
National Health Laboratory Services at Groote Schuur Hospital, where all the samples were 
tested urgently by the laboratory staff.  
Definition of coagulopathy 
For TEG, manufacturer defined criteria were adopted to detect coagulopathy (R time <4 
minutes or >8 minutes, K time >4 minutes,  angle <47 or >74, MA <54 mm or >72 mm, 
EPL>15%, LY30>8%, CI<-3 or >3, G<6.0K or >13.2K). For the conventional laboratory tests, the 
following were used to detect the presence of coagulopathy: platelet count <120 x 109/L, INR 
>1.2, PTT >37 seconds.  
STATISTICAL ANALYSIS 
Data were collated in an Excel (version 15.30, © 2017 Microsoft, Redmond, WA, USA) 
spreadsheet for further analysis. Allocation to groups and within group counting was 
performed using pivot tables in Excel. Where appropriate, correlation was tested using 
STATISTICA (version 13.2, © 2017 Dell Inc., Tulsa, OK, USA).  Distributive data relating to the 
numbers of patients in the various groups were conducted using Chi-square analysis. TEG 
variables were compared across the three time intervals using ANOVA (analysis of variance) 
for repeated measures.  The volumes of fluid given to each category of coagulation patient 
(normal, and hypo- and hypercoagulable groups) were tested for significance using a one-way 
ANOVA. Lilliefors test was used to assess independent TEG variables. Spearman correlation 
was used to assess correlation. The strength of the association was assessed by means of the 




Of the 50 patients recruited for the study, 47 (94%) were male. Median values of AIS head 
and AIS body were 5 and 1 respectively. The median worst GCS was 5, with 38 patients 
requiring intubation prior to arrival at GSH (19 on scene, 19 at the referring hospital). Thirty-
four of the patients suffered from blunt, and the remaining 16 penetrating injuries. Median 
Rotterdam and Marshall scores were 3 and 4 respectively (Appendix F). Sixteen patients 
demised during the course of the study, with 9 demising before the second (36 hour) sample 
could be drawn. There were 109 sample points in the study, of which 59 were 
hypercoagulable by TEG, only 10 were hypocoagulable and the remaining 40 were normal. 
Please see Appendix G for descriptive statistics. 
Conventional blood tests (CBTs) are poorly geared to detect hypercoagulability, so as 
expected, none of the samples met the criteria for hypercoagulability. Of the 109 samples, 72 
were found to be hypocoagulable. Of these, 69 samples met the preset criteria for 
hypocoagulability by means of raised INR, and only 3 met the PTT criteria. There was a very 
poor correlation between hypocoagulability on CBTs and coagulation status as seen on TEG. 
In fact, many of the hypercoagulable TEGs were associated with a raised INR. (Appendix H) 
Thirteen samples met the platelet criteria for a hypocoagulable state. Of these, 11 samples 
were associated with a hypercoagulable or normal TEG, while only two were associated with 
a hypocoagulable TEG. Of the total of 10 thrombocytopenic patients, only 3 were 
thrombocytopenic on presentation, with 6 becoming thrombocytopenic at either the second 
(n=4) or third (n=2) sampling point. One patient did not have a valid platelet result at the T1 
due to platelet clumping noted in the laboratory, but had two further samples that were 
thrombocytopenic (with no further platelet clumping noted). 
Of the CBTs, only the aPTT displayed some relationship with the coagulation status on the 
TEG. The mean aPTT ratio amongst the hypercoagulable patients was 0.94 whereas that of 
the hypocoagulable patients was 1.03. However, marked variation in aPTT ratios, ranging 
from 0.91 to 0.16, was observed in hypocoagulable patients. Since there were only 10 samples 
in this group, any interpretation of the results must be done with caution. (Appendix I) 
No significant difference is evident in either the numbers or type (hypo- or 
hypercoagulopathy) of coagulopathy between blunt and penetrating mechanisms of injury at 
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any given time. (Appendix J) Amongst those who suffered blunt trauma, 46 of the 85 TEGs 
were hypercoagulable, and 6 were hypocoagulable. In the penetrating injury group, 13 of the 
24 samples were hypercoagulable and only 4 samples were hypocoagulable.  
Sixteen patients demised during the course of the study. Of those that died, three were 
hypocoagulable (one patient only had one sample, the other two were hypocoagulable by 
TEG at T1 and then normal at T2), 10 were hypercoagulable (all 10 at T1, 4 survived to have a 
sample at T2; of which all were normal) and the remaining three (two had only one sample) 
showing normal coagulation status. (Appendix K) 
None of the study patients had received any blood or blood products prior to recruitment. 
The decision to administer blood and blood products after recruitment was made by the 
neurosurgical team and was based on the patients’ clinical state. This resulted in a total of 8 
patients receiving packed red blood cells. No platelets or coagulant containing blood products 
were administered to any of the study patients. Of those that received packed red blood cells 
(PRBC), two patients were hypocoagulable at some point in the study. Of these, one was 
hypocoagulable by TEG at the first sampling point (prior to the administration of any PRBC, 
normal INR and platelet count), and remained hypocoagulable at the second sampling point 
(720 ml PRBC administered, normal INR, platelet count=101 x 109/L). The other patient was 
hypercoagulable by TEG at the first sampling point (prior to the administration of any PRBC, 
normal INR and platelet count) and became hypocoagulable by TEG (prolonged R time) at the 
second sampling point (720 ml PRBC administered, normal INR and platelet count). The other 
6 either displayed features of a sustained hypercoagulable or normal coagulation state on 
TEG. Three patients developed a low platelet count following transfusion of significant 
volumes of packed red blood cells (960 mL [plt = 87, normal TEG], 1080 mL [plt=80, normal 
TEG] and 720 mL [plt 101, hypocoagulable TEG with low MA and G value]).  
Four patients received synthetic colloids (hydroxyethyl starch with a substitution ratio of 
130/0.4 [®Fresenius Kabi Norge A.S., Halden, Norway]) prior to recruitment to the study. An 
additional 7 patients received synthetic colloids after recruitment. Of these 7, 3 also received 
PRBC as a part of their resuscitation. Interestingly, none of the patients that received colloids 
displayed any features of a hypocoagulable state on TEG.  
Twenty-two patients had 24 neurosurgical interventional procedures. Of these, 9 patients had 
insertion of neuromonitors only, 5 had a craniotomy for washout of a collection, 8 had both 
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craniotomy and insertion of monitors in a single procedure, and 2 had other procedures (1 
patient had an extraventricular drain inserted, and the other had digital subtraction 
angiography and removal of a penetrating object in theatre). 
We have attempted to describe the coagulation trends found in this study. (Appendices L and 
M) All TEG variables were normally distributed. The individual TEG criteria were assessed to 
determine whether any of them showed a strong link with overall coagulation status and fluid 
balance. Of these, K time and MA showed weak correlation coefficients (0.21 and -0.26 
respectively) with fluid balance.  
Hypocoagulable patients detected by TEG criteria at the T1 had received more fluid than the 
other subgroups (mean fluid balance 3930 mL in the hypocoagulable group vs. 2383.13 mL 
and 1748.57 mL in the normal and hypercoagulable groups, respectively), despite having 
similar severity of injury (median AIS head 5 in the normal and hypercoagulable groups and 
5.5 in the hypocoagulable group; median AIS body was 1 across all groups). Similarly, 
hypocoagulable patients detected by TEG criteria at T2 had a mean interval fluid balance of 
1116.67 mL vs. 296.32 mL and 521.15 mL in the normal and hypercoagulable groups, 
respectively. However, both subsets of hypocoagulable patients were small (6 and 3 at T1 and 
T2, respectively), so these differences did not achieve any statistical significance.(Appendix G 
and N) Interestingly, the hypocoagulable group at T1 had a lower systolic blood pressure 
(93.83 vs. 123.19 and 121.11mmHg in the normal and hypercoagulable groups, respectively) 
and higher pulse rate (107.5 vs. 89.81 and 94.32 bpm [beats per minute] in the normal and 
hypercoagulable groups, respectively) despite similar severity of injuries (median AIS head 
5.5 in the hypocoagulable group vs. 5 in the normal and hypercoagulable groups; and AIS 
body 1 across all groups).(Appendix G and O) Interestingly, the hypercoagulable group had a 
slightly higher base deficit at T1 (-5.096 vs. -4.769 and -4.383 in the normal and 
hypocoagulable groups, respectively) when compared to the other two groups. There was no 
significant difference in pH amongst the groups at T1.  
DISCUSSION 
To the best of our knowledge, this is the first study to examine the coagulation status of fifty 
isolated and severely head-injured patients over multiple time points. Furthermore, this is the 
first study to compare coagulopathy by means of both conventional blood testing and 
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viscoelastic testing in these patients. The main finding of this study is that a hypocoagulable 
state as determined by TEG is much less prevalent than would be expected by reports in the 
literature.1-3 A hypocoagulable state as determined by CBT was detected in 66 percent of 
samples. There was poor congruence between the two testing modalities, with patients 
displaying features of a hypocoagulable state by means of CBT having features of a 
hypercoagulable (37 samples) or normal (25 samples) state on TEG. We intentionally 
employed traditionally used cutoff values for CBT in this study with the aim of making our 
results comparable to the literature. While this may be partially responsible for the large 
number of samples displaying a hypocoagulable state as detected by CBT, it serves to 
question the clinical relevance of these cutoff values. Furthermore, we have detected that 
over 50 percent of samples were hypercoagulable by TEG. By closely examining the trends in 
coagulation over time, we have shown that there is little evidence of an initial 
hypercoagulable state being followed by a hypocoagulable state, as would be expected in a 
consumptive coagulopathy. This calls into question one of the main proposed theories of 
coagulopathy in TBI. 
Windelov et al also reported a low prevalence of hypocoagulability as diagnosed on TEG 
(10%), although they also reported a low prevalence as diagnosed by CBT (21%).4 This may be 
due to a number of reasons. Conventional blood tests that were being used previously, such 
as INR, aPTT and platelet count are static tests and demonstrate poor sensitivity for 
monitoring the dynamic process of coagulation.2 aPTT evaluates factors I, II, V, VII, IX, X XI and 
XII, which form the intrinsic and common final pathways, and is primarily used to monitor 
heparin anticoagulation.5 Prothrombin time (PT) and its derived measure, INR, are used to 
evaluate the extrinsic and common final pathways of coagulation. This includes factors I, II, V, 
VII and X. PT was initially developed to aid in therapeutic anticoagulation monitoring with 
vitamin K antagonists. In the early 1980s, the INR was developed to standardize the 
expression of the prothrombin time ratio and hence minimize the intercenter variation due 
to the use of different reagents. Both INR and aPTT are in vitro tests performed on citrated, 
platelet poor plasma, and are not temperature sensitive. The in vitro nature of these tests has 
an important interpretive implication, as any condition in which coagulation may occur due 
to accelerated cellular function (e.g. platelets) may be missed. 
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Raised PT and INR have been implicated to be associated with an increased risk of progressive 
hemorrhagic injury (PHI), resultant irrevocable loss of brain tissue and unfavorable outcome 
in a multitude of studies.6-14 A recent meta-analysis investigating the correlation between 
coagulopathy in TBI and PHI reported a pooled difference in means of 0.07 (CI 95% 0.02-0.13; 
p=0.0006).15 This does not seem to be a significant difference, especially when it is noted that 
3 of the 6 studies reported little to no difference. A recent prospective observational study in 
trauma patients who received fresh frozen plasma (FFP) transfusion found that while 
administration of FFP resulted in a reduction in INR, median TEG values remained within 
normal limits and clotting factor levels retained adequate function to produce normal clotting 
both before and after FFP transfusion.16 Interestingly, patients who had a raised INR (>1.4), 
the median time to neurosurgical intervention (NI) was longer (358 minutes [285-478 
minutes] vs. 231 minutes [96-363 minutes]), and were more likely to receive a monitoring 
device as their sole NI.17 The investigators found no association between high INR and any 
individual abnormal TEG parameter.16 Furthermore, when considering patients with similar 
presenting GCS and AIS head, FFP transfusions alone (OR 5.20 [CI 95% 1.72-15.730]) or in 
combination with PRBCs (OR 7.17 [CI 95% 2.12-24.12]) were associated with poorer long-term 
functional outcomes as measured by Glasgow outcome scale – extended (GOSE).18 Low dose 
recombinant factor VIIa (rFVIIa) has been shown to be effective in correcting coagulopathy 
(INR>1.2 or platelet count<100 x 109/L) and hence preventing PHI without an increased risk 
for thromboembolic events.7 
Thrombocytopenia has previously been linked to increased mortality at 6 months, but has 
only been reported in 7-10% of TBI patients.19 In contrast, in our study, 10 patients (20%) 
were thrombocytopenic (platelet count<120 x 109/L). This may be attributed to the overall 
severity of head injuries in our sample.  It is noteworthy that of the 13 thrombocytopenic 
samples, 11 had normal or hypercoagulable TEGs. This implies that a low absolute platelet 
count does not necessarily mean hypocoagulability. G value, a calculated parameter reflecting 
clot strength, has been reported to be a more sensitive measure of platelet function.20, 21 No 
clear relationship between G value and platelet count was noted in our study.(Appendix P) 
The lack of association between platelet count and hypocoagulability by CBT is not in 
agreement with the results of a meta-analysis from 2016, which indicated that PHI was 
significantly associated with a platelet count <100 x 109/L.15 It seems that the converse has 
38 
 
also been noted in the literature, viz. the presence of a normal platelet count does not 
preclude clinically significant bleeding tendencies.22 However, in that study, six of the 20 TBI 
patients received extensive haemostatic treatment in the form of plasma, desmopressin, 
tranexamic acid and platelet concentrates, making the results difficult to interpret. While 
thrombocytopenia has been associated with an increased risk of progressive hemorrhagic 
injury,6 so have certain CT findings, such as the presence of intraparenchymal contusions of a 
certain size.9, 23 Evidence seems to be growing that platelet function rather than absolute 
platelet count is likely to be more informative when assessing coagulation status in brain-
injured patients.22 
In contrast to previous reports, we found a much higher proportion of hypercoagulable 
patients in our study sample.1, 3 Of the 109 samples, 59 were found to be hypercoagulable by 
TEG. Thirty-four patients in our study were hypercoagulable by TEG at some time point and 
only 2 of those patients became hypocoagulable at any time point. This seems to imply that 
a DIC type picture is far less common than previously thought. Five patients that were 
categorized as hypercoagulable on TEG that demised prior to the second sample. It is possible 
that they may have become hypocoagulable at some time point had they survived longer, 
which could make it erroneously appear that the number of patients displaying features of 
DIC is smaller. Hypothetically, if all five of those patients would become hypocoagulable still 
leads to a much smaller proportion (14%) of patients displaying features of DIC than reported 
in the literature (33-35%).1  
Hypercoagulability as diagnosed by TEG is documented in trauma.24 A small study (n=25) 
found that all of their patients were hypercoagulable by manufacturer defined criteria for 
both MA and G value between day 4 and day 5 following TBI.20 Unfortunately, our study was 
only able to follow up patients up to 60 hours post injury. Despite this, we also showed a 
sustained hypercoagulable state. Furthermore, thromboelastometric (ROTEM) analysis 
showing shorter clotting times and higher clot firmness has been linked with survival in a 
recent study.25 While native TEG and ROTEM parameters are significantly different in trauma 
patients, celite activated samples can be considered comparable.26  
Assuming clotting cascade activation is a consequence of massive tissue factor release from 
the injured brain, we postulated that penetrating injuries that result in severe traumatic brain 
injury may be a particularly ‘at risk’ group for coagulopathy. We did not find any significant 
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differences in the number or type of coagulopathy as diagnosed by TEG between the blunt 
and penetrating trauma groups at any time, which is consistent with findings in a previous 
report.27 Interestingly, in that study, there was a slightly higher proportion of moderate (GCS 
9-12) and severely (GCS8) injured patients in the penetrating group (80%) when compared 
to the blunt group (68.5%). 
The severity of head injuries in those that demised was such that many of these patients were 
deemed unsalvageable and their deaths were expected. These patients were provided all 
supportive treatment, but were not managed actively (i.e. not taken to theatre for ICP 
monitor placement or admitted to ICU for further management). Many of them remained in 
the trauma unit. Literature often excludes patients who are deemed unsalvageable, often 
leading to an underestimate in mortality in head injury outcome studies.28, 29 In the present 
study, there were no differences in numbers or type of coagulation abnormalities in the 
subgroup that demised during the course of the study, the median AIS head was higher (6 vs. 
5), and the median AIS body was similar (both 1) to the study population overall.  
Improvements in our understanding of the cell-based nature of coagulation and the role of 
tissue factor and platelets, have necessitated the development and use of tests that can 
provide more reliable information regarding in vivo hemostasis.30-32 TEG and ROTEM are two 
such tests which can provide information about all the stages of hemostasis – from clot 
development to fibrinolysis. The fact that point-of-care (POC) test results are rapidly available 
to provide a clinically useful approach to targeted blood product administration in hemostatic 
resuscitation leads to reduced blood product transfusion (73.1% vs. 53.9% [p=0.03]), 
reductions in FFP administration when compared to INR triggers (26.9% vs. 65.5% [p=0.003]) 
and improved clinical outcomes.33 In addition to the obvious reduction in potential harm to 
the patient by administration of fewer blood products, preservation of life-saving resources 
in a resource poor environment is crucial.  
POC coagulation testing has some limitations. Firstly, the availability of the equipment and 
knowledge to run the test accurately to achieve consistent results is a hurdle in both 
developed and developing countries.34 Secondly, while it is possible to adjust the temperature 
of the test, it is not routinely done. Failure to do so in hypothermic patients can mask the 
severity of coagulopathy. Lastly, these tests are not geared to assess endothelial contribution 




The literature surrounding TBI defines severe GCS as being less than eight, but does not 
subdivide it into any further levels, likely because GCS is not a linear scale.22, 35-37 While GCS 
may be a useful surrogate measure of injury severity, and hence aid to triage and 
prognosticate injury trajectory, it does not equate to outcome.38 Accordingly, we have 
selected the most severely injured patients by only recruiting those with a GCS of less than 
eight, but have not further subdivided the patients into categories based on their GCS. GCS 
can be greatly influenced by external factors such as sedation, whether iatrogenic or self-
inflicted. Furthermore, GCS is time sensitive; a rapid deterioration in GCS may imply more 
urgency when compared to a gradual decline.  
The aim of CT classification of head injuries in this study was to ensure that patients who 
presented with a low GCS had significant cerebral injuries to account for the low GCS, and 
hence to decrease the risk of recruiting inappropriate patients. In this study, we have 
presented data for both Rotterdam and Marshall scores for each individual patient (Appendix 
F). While both are validated scoring systems in TBI, the sensitivity and specificity may differ 
due to the dichotomous nature of scoring systems. One study suggested that while the 
Marshall score has good predictability when assessing mortality, the Rotterdam score may be 
better for prognostication.39 We had a significant difference in calculated scores. While 24 
patients had a Marshall score of 4, only 8 patients had a Rotterdam score of 4. There was no 
clear association between the score and the presence of coagulopathy on TEG. This is a 
descriptive study, with the potential to assist in planning future studies targeted at evaluating 
these two scoring systems. Hence, we have reported both scores for each patient.  
A recent study showed a significant gender difference in TEG variables, with healthy female 
patients to be slightly hypercoagulable when compared to their male counterparts.40 Female 
patients had a shorter R time (6.3 [5.2-8.2] vs. 8 [6.8-8.9]; p=0.012) and K time (2.1 [1.8-2.4] 
vs. 2.9 [2.6-3.2]; p<0.001), larger  angle (59.111.0 vs. 51.18.1; p<0.001) and larger MA 
(59.45.8 vs. 54.35.6; p=0.001). Most (94%) of the patients in the present study were male, 
reflecting our typical TBI patients, which makes the presence of a hypercoagulable state as 
diagnosed by TEG significant. 
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Two studies have shown a difference between simultaneously drawn arterial and venous 
samples and TEG variables.41, 42 In both studies, there was a significant difference between 
the arterial and venous catheter sizes (20 G arterial catheter, vs 9F central venous sheath vs 
7F pulmonary artery catheter in one study; and although size is not explicitly stated in the 
other, the comparison done was between an arterial catheter and a central sheath, therefore 
a significant difference in lumen diameter is likely). It seems that significant shear force from 
the smaller lumen diameter may result in platelet aggregation, which may account for the 
differences seen (CVC [central venous catheter] R time 8.42.7 vs. arterial R time 9.83.1 vs. 
central sheath R time 12.74.8; p=0.004 and CVC MA 60.411.7 vs. arterial MA 56.211.4 vs. 
central sheath 50.513.3; p=0.008), rather than whether the sample was drawn from an 
arterial or venous site. In the present study, when patients had a functioning arterial catheter 
in situ, it was deemed unethical to obtain a venous sample and therefore blood was drawn 
via the arterial catheter. While it is possible that this may affect the results, similar gauges 
were used for both samples (20 G, 5 cm arterial catheters are used most commonly at our 
institution, and 20 G needles were used for phlebotomy). Furthermore, since all samples were 
drawn by a single investigator, the negative pressure applied during blood drawing is likely to 
be similar and unlikely to be the source of the differences seen.  
While we endeavored to document parameters such as temperature and clinical evidence of 
alcohol at presentation, much of the data was not available, and hence detailed analysis of 
these parameters could not be pursued. Interestingly, while patients with more severe brain 
trauma are more likely to have an early and consistent pyrexia and prolonged stay in ICU, 
predicted probability of death increased as brain temperature dropped below 36C.43 We 
found no appreciable difference in temperature trends when divided by coagulation status, 
although patients who demised during the course of the study seemed to have a trend 
towards a higher temperature.(Appendix Q) Acute alcohol intoxication can reportedly make 
TEG measurements (prolonged R and K times and decreased  angle) appear relatively 
hypocoagulable when compared to non-intoxicated trauma patients.44 Surprisingly, acute 
alcohol intoxication is associated with a significantly lower incidence of in-hospital mortality 
and lower frequency of coagulopathy by conventional blood testing on admission, despite 
similar severity of injury by AIS head scoring.45 One possible confounder in that study was the 
use of pharmacological alcohol withdrawal prophylaxis in the form of barbiturates, 
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benzodiazepines, dexmedetomidine or propofol, all of which decrease cerebral metabolism 
and hence may have had some protective effect.  
Management of fluid balance and fluid choice is a crucial part of the treating any critically ill 
patient. Overall, at our institution, patients with TBI tend to receive slightly hypernatremic 
fluids, such as normal saline, with an aim to avoid cerebral edema. In a porcine model of TBI 
and hemorrhagic shock, normal saline was associated with early activation of coagulation, 
anticoagulation and endothelial systems when compared to FFP and colloid resuscitation. 
Furthermore, the use of normal saline may play a role in electrolyte abnormalities such as 
hypernatremia and hypokalemia which complicate patient management.46 While we noticed 
a trend of a more positive fluid balance in the hypocoagulable group at T1, the numbers were 
too small to pursue any meaningful statistical analyses.(Appendix N) A small retrospective 
human study found no association between cumulative fluid balance and the development 
of refractory intracranial hypertension, but did note a strong association with the 
development of pulmonary edema (HR 1.69 [CI 95% 1.40-2.04, p<0.001]).36 High or low 
cumulative fluid balances (>3673 mL [60782112 mL] and <637 mL [-389941 mL] 
respectively) are associated with poor short-term outcomes. 47 While four patients received 
synthetic colloids (HES 130/0.4) prior to recruitment to the study, and an additional 7 received 
synthetic colloids after recruitment (of which 3 also received PRBC in addition to colloids), 
none of these patients displayed any features of a hypocoagulable state on TEG. None of the 
study patients had received any blood or blood products prior to recruitment to the study. Of 
the 8 patients that subsequently received PRBC after recruitment, only 2 were 
hypocoagulable by TEG. It seems that dilutional coagulopathy is unlikely to be the sole 
contributor to presence of a hypocoagulable state.  
While some differences were noted in presenting vitals (lower mean systolic blood pressure 
and higher mean pulse rate, Appendix O) amongst the hypocoagulable group when compared 
to the hypercoagulable and normal groups, none of these were statistically significant due to 
the small numbers of hypocoagulable patients in the study. This finding is contrary to a 
previous report which found that patients with a prolonged R time at admission TEG had a 
higher admission mean arterial blood pressure (129 vs. 101 mmHg) and pulse rate (99 vs. 89 
beats per minute).48 Unfortunately, the investigators did not indicate how many of their 69 
study patients were in the hypocoagulable group. 
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South Africa, a developing country, has the fourth highest adult human immunodeficiency 
virus (HIV) prevalence (19.1%) worldwide, as well as a high incidence rate of tuberculosis(TB) 
(834 per 100000 in HIV positive cases and 509 per 100000 in HIV negative cases).49, 50 Both of 
these conditions are known to be associated with a relatively hypercoagulable state.51, 52 It is 
highly likely that some patients in this study may have undiagnosed HIV or TB despite the lack 
of clinical features of either illness, and it is possible that this could have affected the 
coagulation testing.  
This study has a number of strengths and limitations that merit discussion. To the best of our 
knowledge, this is the first study to look at both conventional blood testing and viscoelastic 
testing in severely brain injured patients longitudinally, while excluding patients with other 
significant injuries. We therefore report the findings in 50 isolated and severely head-injured 
patients.  
This was a single center study, and all the limitations of a single center study apply. Of note, 
our hospital is one of the two tertiary level public hospitals in the province that are equipped 
to manage traumatic brain injury. However, it is difficult to extrapolate these results to the 
entire population as the patient demographics may differ. We were not able to do concurrent 
TEG platelet mapping studies or fibrinogen levels, which may have yielded interesting results. 
Unfortunately, certain data is unavailable due to differing documentation styles of the 
admitting staff – for example the presence of clinical evidence of ethanol intoxication, and 
temperature upon arrival. Many of the patients in the study were unidentified at the time of 
presentation to the hospital and during the study, thus the availability of collateral and 
background medical history was limited. Certain recorded parameters such as details of fluid 
administration, urine output and interim vitals were taken from the patients’ records. There 
is always a possibility that some of this data could be missing, underestimated or erroneously 
recorded in a typical busy hospital setting. Referral notes for patients referred on via a 
primary or secondary hospital were scrutinized, however the information provided was of 
varying quality and the possibility of missing some data exists.  
There are a number of strengths to this study. One investigator recruited all the study 
patients, performed all venipunctures, blood sampling and running of TEG samples, thus 
eliminating much bias, as well as sampling and test errors. All the data were also captured by 
the same investigator in a systematic manner. The possibility of misreporting of data is thus 
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minimized. All CT scans were evaluated and scored by a single investigator to maintain 
consistency of scoring.  
CONCLUSION 
Contrary to what is reported in the literature, we found little evidence of a hypocoagulable 
state as defined by TEG (10 of the 109 samples) in severely brain-injured patients that 
presented to Groote Schuur Hospital. On the contrary, many patients were significantly 
hypercoagulable (59 of the 109 samples) according to criteria specified by the TEG 
manufacturer. When considering the CBT results, we had a much higher number of 
hypocoagulable samples (72 of the 109 samples), with none showing a hypercoagulable state. 
Moreover, there was poor correlation between coagulation status as measured by TEG 
described and that found on conventional blood testing. No significant differences in the 
prevalences of coagulopathy amongst blunt and penetrating mechanisms of injury were 
noted. Some differences in fluid balance and presenting vitals in the hypocoagulable group 
when compared to the normal and hypercoagulable groups were noticed, but this does not 







Abbreviated Injury Score 
The Abbreviated Injury Scale (AIS) is an anatomical-based coding system created by the Association for 
the Advancement of Automotive Medicine to classify and describe the severity of injuries. It represents 
threat to life associated with the injury rather than a comprehensive assessment of severity of the injury. 
The score describes 3 aspects of the injury - type, location and severity.  
Type indicates which anatomical structures are involved: 
1. Whole area 
2. Vessels 
3. Nerves 
4. Organs (including muscles and ligaments) 
5. Skeletal (including joints) 
6. Loss of consciousness (head) 







7. Upper extremity 
8. Lower extremity 
9. Unspecified 
Severity of injuries is classified as follows: 
1. Minor - 0% probability of death 
2. Moderate - 1-2% probability of death 
3. Serious - 8-10% probability of death 
4. Severe- 5-50% probability of death 
5. Critical - 5-50% probability of death 




The Glasgow Coma Scale  
It is used to assess the level of consciousness following head injury, especially by means of serial 
evaluations. Three responses are assessed; eyes, verbal and motor, with a minimum score of 3 and a 
maximum score of 15.  
 Eyes Verbal Motor 
1 No eye opening Makes no sounds Makes no movements 
2 Opens eyes to painful stimulus Incomprehensible sounds Extension to painful 
stimulus (decerebrate 
posturing) 
3 Opens eyes to verbal command Inappropriate words Abnormal flexion to painful 
stimulus (decorticate 
posturing) 
4 Spontaneous eye opening Confused, disoriented Flexion/withdrawal to 
painful stimulus 
5 N/A Orientated, converses 
normally 
Localizes painful stimulus 







Normal TEG values as specified by the manufacturer 
1. R time (reaction time, time to first measurable clot formation): 4-8 minutes 
2. K time (achievement of a certain clot firmness): 0-4 minutes 
3.  angle (kinetics of clot development): 47-74 degrees 
4. MA (maximum amplitude, maximum strength of clot): 54-72 mm 
5. LY30 (percent lysis 30 minutes after MA): 0-8% 
6. EPL (estimated percent lysis): 0-15% 
7. Coagulation Index (linear combination of R, K,  angle and MA): -3-3  





Normal laboratory values as specified by the NHLS 
1. Platelet count 171-388x109/L 
2. Sodium: 136-145 mmol/L 
3. Potassium: 3.5-5.1 mmol/L 
4. Urea: 2.1-7.1 mmol/L 
5. INR 0.8-1.0 





Criteria for repeat blood sampling at 60 hours post injury (20% outside of the normal values 
for coagulation testing and 10% outside the normal values for electrolyte abnormalities) 
1. Sodium <123 or >159 mmol/L 
2. Potassium <3.15 or >5.61 mmol/L 
3. Platelet count <120x109/mL or >540x109/mL 
4. INR <0.6 or >1.4 
5. PTT <16 seconds or >43 seconds 
6. TEG  
• R time <3 minutes or >10 minutes 
• K time >5 minutes 
• α angle <38 degrees or >88 degrees 
• CI <-4 or >4 
• EPL >20% 





Details of CT scans 
1. CT characteristics of head injuries 
2. Numbers of patients by Marshall and Rotterdam scores 
3. Details of CT scoring 
 
Table 1 
CT characteristic Number of patients 




Midline shift ≤ 5 mm 25 
>5 mm 24 
Total 49 








Intracerebral lesions Absent 12 
High or mixed 
density, ≤ 25 cm3 
34 
High or mixed 







 1 2 3 4 Total 
Rotterdam score 9 9 23 8 49 






















1 Absent ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 3 
2 Absent ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 3 
3 Compress
ed 
≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 2 3 
4 Compress
ed 
> 5mm Absent Present Absent No 3 4 
5 Compress
ed 
> 5mm Absent Present Absent No 3 4 
6 Absent ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 3 
7 Normal ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 1 2 
8 Normal ≤ 5 mm Absent Absent High or 
mixed, ≤ 
25 cm3 





> 5mm Absent Present Absent No 3 4 
10 Compress
ed 
> 5mm Present Present High or 
mixed, ≤ 
25 cm3 
No 2 4 
11 Normal ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 1 2 
12 Compress
ed 
≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 2 3 
13 Absent > 5mm Absent Present Absent No 4 4 
14 Normal ≤ 5 mm Absent Present Absent No 1 2 
15 Absent > 5mm Absent Present Absent No 4 4 
16 Compress
ed 
> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 4 
17 Compress
ed 
> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 4 
18 Compress
ed 
> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 4 
19 Compress
ed 
> 5mm Absent Present Absent No 3 4 
20 Absent > 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 4 4 
21 Compress
ed 
> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 4 
22 Compress
ed 
≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 2 3 
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23 Absent ≤ 5 mm Present Absent High or 
mixed, ≤ 
25 cm3 
No 3 3 
24 Compress
ed 
≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 2 3 
25 Normal ≤ 5 mm Absent Present Absent No 1 2 
26 Compress
ed 
≤ 5 mm Present Present High or 
mixed, ≤ 
25 cm3 
No 1 3 
27 Absent ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 3 
28 Compress
ed 
> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 4 
29 Absent > 5mm Absent Present Absent No 4 4 
30 Normal ≤ 5 mm Absent Present Absent No 1 2 
31 Normal > 5mm Present Absent Absent No 2 4 
32 Absent > 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 4 4 
33 Absent > 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 4 4 
34 Compress
ed 
> 5mm Absent Present High or 
mixed, 
>25cm3 
No 3 4 
35 Normal ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 1 2 
36 Compress
ed 
≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 





> 5mm Absent Present High or 
mixed, 
>25cm3 
No 3 4 
38 Compress
ed 
> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 4 
39 Normal ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 1 2 
40 Absent > 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 4 4 
41 Absent ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 3 
42 Absent ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 3 
43 Compress
ed 
≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 2 3 
44 Absent ≤ 5 mm Absent Present High or 
mixed, 
>25cm3 
No 3 3 
45 N/A N/A N/A N/A N/A N/A   
46 Absent > 5mm Absent Present Absent No 4 4 
47 Absent ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 3 
48 Compress
ed 
> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 
No 3 4 
49 Normal ≤ 5 mm Absent Present High or 
mixed, ≤ 
25 cm3 





> 5mm Absent Present High or 
mixed, ≤ 
25 cm3 






Descriptive statistics by 12 hour TEG coagulation status 
  Normal Hypocoagulable Hypercoagulable 
Patients Number 16 6 28 
Age Mean years 33.75 24.05 31.06 
Mechanism of 
injury 
Number of blunt 13 3 20 
Number of 
penetrating  
3 1 8 
AIS head Median 5 5.5 5 
AIS body Median 1 1 1 
Worst GCS Median 5.5 4 5 
Location of 
intubation 
On scene 5 1 13 
Referring hospital 5 4 10 
Groote Schuur 
Hospital 
6 1 5 
Vitals Mean systolic blood 
pressure 
123.19 93.83 121.11 
Mean pulse rate 89.81 107.5 94.32 
Mean pH 7.323 7.33 7.326 
Mean base deficit -4.769 -4.383 -5.096 
Mean lactate 3.356 4.5 4.125 
Average fluid 
balance 
Mean 2383.13 3930 1748.57 
CT Marshall score Median 3 4 4 
CT Rotterdam 
score 
Median 2 3 3 
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Conventional blood testing and coagulation status by TEG: 
1. aPTT ratio by TEG coagulation status 
2. aPTT ratio by time 
3. INR 











Coagulation status according to TEG by mechanism of injury and time point 
 
  





T1 T2 T3 
Blunt 
Hypercoagulable 20 16 10 46 
Hypocoagulable 3 2 1 6 
Normal 13 15 5 33 
No sample 0 3 20 23 
Penetrating 
Hypercoagulable 8 3 2 13 
Hypocoagulable 3 1 0 4 
Normal 3 4 0 7 
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TEG variable trends by time 
1. R time 
2. K time  
3. α angle 
4. MA 
5. CI  





























Vital signs by TEG coagulation status: 
1. Systolic blood pressure (SBP) 
2. Mean arterial blood pressure (MAP) 









Relationship between G value and platelet count 


































1. By TEG coagulation status 
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LIST OF ABBREVIATIONS 
Abbreviation Description 
AA arachidonic acid 
ADAMTS-13 a thrombospondin type 1 motif, member 13 
ADP adenosine diphosphate 
AIS abbreviated injury scale 
aPTT activated partial thromboplastin time 
BBB blood-brain barrier 
CBT conventional blood test 
CI confidence interval 
CI coagulation index 
CT computed tomography 
DIC disseminated intravascular coagulation 
DVT deep venous thrombosis 
EDTA ethylenediaminetetraacetic acid 
EPL estimated percentage of lysis 
FDP fibrin degradation product 
FFP fresh frozen plasma 
FXI factor XI 
FXIIa activated factor XII 
GCS Glasgow coma scale 
GOS Glasgow outcome scale 
GOSE Glasgow outcome scale – extended 
GSH Groote Schuur Hospital 
HIV human immunodeficiency virus 
HR harm ratio 
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ICP intracranial pressure 
ICU intensive care unit 
IF interferon 
IL interleukin 
IMPACT International Mission on Prognosis and Analysis of Clinical Trials in TBI 
INR international normalized ratio  
LY30 clot lysis at 30 minutes after MA 
MA maximum amplitude 
MAP mean arterial blood pressure 
MD mean difference 
MP microparticle 
NI neurosurgical intervention 
OR odds ratio 
PAF platelet-activating factor 
PAI plasminogen activator inhibitor 
PHI progressive haemorrhagic injury 
PLT platelet count 
POC point-of-care 
PR pulse rate 
PRBC packed red blood cell 
PT prothrombin time 
R time reaction time 
rFVIIa recombinant factor VIIa 
ROTEM thromboelastometry 
SBP systolic blood pressure 
T0 time 0, time of injury 
T1 time 1, 12 hours (±3 hours) after T0 
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T2 time 2, 36 hours (±3 hours) after T0 
T3 time 3, 60 hours (±3 hours) after T0 
TACO transfusion associated circulatory overload 
TB tuberculosis 
TBI traumatic brain injury 
TEG thromboelastography 
TGF transforming growth factor 
TNF tumour necrosis factor 
tPA tissue plasminogen activator 
TRALI transfusion related acute lung injury 
VET viscoelastic testing 
 
